In Vivo Tissue-Engineered Vascular Grafts - Archive ouverte HAL Accéder directement au contenu
Chapitre D'ouvrage Année : 2020

In Vivo Tissue-Engineered Vascular Grafts

Résumé

Vascular grafts are needed for coronary and peripheral vascular bypass surgeries as well as for access surgeries for hemodialysis and reconstruction of congenital heart defects. Despite good results in the large caliber, small caliber (<6 mm) show unsatisfactory clinical results. Tissue-engineered vascular grafts (TEVG) have been made using several approaches ranging from acellular synthetic or biologic polymer scaffolds to decellularized natural matrices, self-assembled cell-based bioreactor matured, or 3D cell-printed constructs. This chapter will focus mainly on in vivo tissue engineering which was used as first-in-man. This is based on an acellular, synthetic, degradable, polymer scaffold which is repopulated by the host cells after implantation to create a “neo-artery.” Advantages are shelf-readiness; simple, cost-effective manufacturing; and avoidance of bioreactor cell maturation. Short-, mid-, and long-term experimental and clinical results show good cellular remodeling with extracellular matrix formation and endothelialization as well as patency and function. Thus, the approach of using an acellular, synthetic, biodegradable scaffold is an optimal clinical option for TEVG.
Fichier non déposé

Dates et versions

hal-04326067 , version 1 (06-12-2023)

Identifiants

Citer

Beat Walpoth, Sarra de Valence, Jean-Christophe Tille, Damiano Mugnai, Tornike Sologashvili, et al.. In Vivo Tissue-Engineered Vascular Grafts. Beat Walpoth, Helga Bergmeister, Gary Bowlin, Deling Kong, Joris Rotmans, Peter Zilla. Tissue-Engineered Vascular Grafts, Springer International Publishing, pp.1-21, 2020, Reference Series in Biomedical Engineering (RSBE), ⟨10.1007/978-3-319-71530-8_7-1⟩. ⟨hal-04326067⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More